Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC + Sintilimab + Bevacizumab for BCLC-C HCC
NCT05617430Phase 2Unknown
- Start
- Nov 2022
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, bevacizumab in hepatocellular carcinoma (HCC). Status: unknown.
02
Drugs
sintilimabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05617430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05617430.